Challenges in clinical trials for high-risk but curable prostate cancer

被引：1
|
作者：
Dorff, Tanya Barauskas [1 ,3 ]
Bryce, Alan H. [2 ]
机构：
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
[2] City Hope Phoenix, Dept Med Oncol & Therapeut Res, Phoenix, AZ USA
[3] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, 1500 E Duarte Rd, PAV2250, Duarte, CA 91010 USA
来源：
CANCER | 2024年 / 130卷 / 09期
关键词：
androgen-deprivation therapy; clinical trial recruitment and retention; patient advocate; prostate cancer; prostatectomy;
D O I：
10.1002/cncr.35245
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Clinical trials studying neoadjuvant and adjuvant therapy around prostatectomy for patients with high-risk prostate cancer have faced multiple challenges. Patients who have a very good response to neoadjuvant therapy may not wish to continue to adjuvant treatment, and prostate-specific antigen-based end points are difficult to interpret because of variations in testosterone recovery.
引用
收藏
页码：1575 / 1576
页数：2
相关论文
共 50 条
  • [41] Surgery for high-risk localized prostate cancer
    Schmitges, Jan
    Trinh, Quoc-Dien
    Walz, Jochen
    Graefen, Markus
    THERAPEUTIC ADVANCES IN UROLOGY, 2011, 3 (04) : 173 - 182
  • [42] Is Clinical Stage T2c Prostate Cancer an Intermediate- or High-Risk Disease?
    Klaassen, Zachary
    Singh, Abhay A.
    Howard, Lauren E.
    Feng, Zhaoyong
    Trock, Bruce
    Terris, Martha K.
    Aronson, William J.
    Cooperberg, Matthew R.
    Amling, Christopher L.
    Kane, Christopher J.
    Partin, Alan
    Han, Misop
    Freedland, Stephen J.
    CANCER, 2015, 121 (09) : 1414 - 1421
  • [43] Dose escalation of external beam radiotherapy for high-risk prostate cancer-Impact of multiple high-risk factor
    Umezawa, Rei
    Inaba, Koji
    Nakamura, Satoshi
    Wakita, Akihisa
    Okamoto, Hiroyuki
    Tsuchida, Keisuke
    Kashihara, Tairo
    Kobayashi, Kazuma
    Harada, Ken
    Takahashi, Kana
    Murakami, Naoya
    Ito, Yoshinori
    Igaki, Hiroshi
    Jingu, Keiichi
    Itami, Jun
    ASIAN JOURNAL OF UROLOGY, 2019, 6 (02) : 192 - 199
  • [44] The Central Role of Radiation in Prolonging Survival for High-Risk Prostate Cancer
    Shumway, Dean A.
    Hamstra, Daniel A.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (05) : 18 - 22
  • [45] Neoadjuvant therapies for surgical management of high-risk, localized prostate cancer
    Mikkilineni, Nina
    Hyams, Elias S.
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S662 - S675
  • [46] ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer
    McLaughlin, Patrick W.
    Liss, Adam L.
    Nguyen, Paul L.
    Assimas, Dean G.
    D'Amico, Anthony V.
    Gottschalk, Alexander R.
    Gustafson, Gary S.
    Keol, Sameer R.
    Liauw, Stanley L.
    Lloyd, Shane
    Movsas, Benjamin
    Prestidg, Bradley R.
    Showalter, Timothy N.
    Taira, Al V.
    Vapiwal, Neha
    Davi, Brian J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (01): : 1 - 10
  • [47] High-risk prostate cancer: the role of radical prostatectomy for local therapy
    Ghavamian, Reza
    Williams, Steve K.
    Hakimi, A. Ari
    FUTURE ONCOLOGY, 2011, 7 (04) : 543 - 550
  • [48] Clinical Factors Predicting Bilateral Lymph Node Invasion in High-Risk Prostate Cancer
    Porcaro, Antonio Benito
    De Luyk, Nicolo
    Corsi, Paolo
    Sebben, Marco
    Tafuri, Alessandro
    Processali, Tania
    Mattevi, Daniele
    Pirozzi, Marco
    Cerruto, Maria Angela
    Amigoni, Nelia
    Rizzetto, Riccardo
    Brunelli, Matteo A.
    Migliorini, Filippo
    Siracusano, Salvatore
    Artibani, Walter
    UROLOGIA INTERNATIONALIS, 2017, 99 (04) : 392 - 399
  • [49] Optimization of the Radiation Management of High-Risk Prostate Cancer
    Nguyen, Paul L.
    SEMINARS IN RADIATION ONCOLOGY, 2017, 27 (01) : 43 - 49
  • [50] News and perspective in management of high-risk prostate cancer
    Audenet, F.
    Roupret, M.
    PROGRES EN UROLOGIE, 2011, 21 : S80 - S83
12345